Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Eva Brunnemer (Heidelberg, Germany), Eva Brunnemer, Svenja Ehlers-Tenenbaum, Calus Peter Heussel, Arne Warth, Felix Herth, Michael Kreuter. Real life experience with nintedanib in patients with idiopathic pulmonary fibrosis. Eur Respir J 2016; 48: Suppl. 60, 2093

Member's Comments

No comment yet.

Related content which might interest you: Real life patient experience of pirfenidone in a regional interstitial lung disease clinic Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Onset of symptoms in idiopathic pulmonary fibrosis: A case-control study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Idiopathic pulmonary fibrosis (IPF): the patient journey Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Pirfenidone in patients with advanced idiopathic pulmonary fibrosis: First experience Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 The burden of idiopathic pulmonary fibrosis reported by patients and carers in Ireland Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Does emphysema coexistence with IPF change prognosis? Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 The lived experience of idiopatic pulmonary fibrosis: A qualitative study Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences Year: 2016 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016